Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 1.381 Billion | USD 3.015 Billion | 9.1% | 2022 |
FrequentlyAsked Questions
The global industry stands on the analysis of the cancer cell Deoxyribonucleic acid (DNA) that further helps to identify various associated mutations that cause cell growth.
The global lung cancer genomic testing market is projected to grow owing to the increasing cases of lung cancer across the world. The number one cause of lung cancer is smoking while other factors also contribute to the rising number of patients.
According to study, the global lung cancer genomic testing market size was worth around USD 1.381 billion in 2022 and is predicted to grow to around USD 3.015 billion by 2030.
The CAGR value of the lung cancer genomic testing market is expected to be around 9.1% during 2023-2030.
The global lung cancer genomic testing market is projected to witness the highest growth in North America with the US leading the regional growth.
The global lung cancer genomic testing market is led by players like CD Genomics, Qiagen NV, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Agilent Technologies, Inc., Illumina, Inc., Thermo Fischer Scientific, Inc., Abbott Laboratories, Inc., Quest Diagnostics, Inc., OncoDNA, Centogene N.V., Admera Health, CeGaT GmbH, OPKO Health, Inc., and F. Hoffmann-La Roche AG.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed